Nutritional Status and Health-Related Quality of Life in Men with Advanced Castrate-Resistant Prostate Cancer

References

• Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann Oncol. 2018;29(4):1016–1022. doi:https://doi.org/10.1093/annonc/mdy033
   PubMed Web of Science ®Google Scholar
• Cushen SJ, Power DG, McDermot R, O'Sullivan K, Maceneaney P, Daly L, Ryan AM. Body composition as a predictor of chemotherapy toxicity in patients with metastatic prostate cancer treated with docetaxel (abstr). Proc Nutr Soc. 2015;74(OCE2):E165. doi:https://doi.org/10.1017/S0029665115001834
   Web of Science ®Google Scholar
• van Londen GJ, Levy ME, Perera S, Nelson JB, Greenspan SL. Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. Crit Rev Oncol Hematol. 2008;68(2):172–177. doi:https://doi.org/10.1016/j.critrevonc.2008.06.006
   PubMed Web of Science ®Google Scholar
• Østergren PB, Kistorp C, Bennedbaek FN, Faber J, Sønksen J, Fode M. The use of exercise interventions to overcome adverse effects of androgen deprivation therapy. Nat Rev Urol. 2016;13(6):353–364. doi:https://doi.org/10.1038/nrurol.2016.67
   PubMed Web of Science ®Google Scholar
• Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603. doi:https://doi.org/10.1210/jcem.87.2.8299
   PubMed Web of Science ®Google Scholar
• Alibhai SMH, Breunis H, Timilshina N, Naglie G, Tannock I, Krahn M, Warde P, Fleshner NE, Canning SD, Tomlinson G, et al. Long-term impact of androgen-deprivation therapy on physical function and quality of life. Cancer. 2015;121(14):2350–2357. doi:https://doi.org/10.1002/cncr.29355
   PubMed Web of Science ®Google Scholar
• Parker C, Gillessen S, Heidenreich A, Horwich A, Committee EG. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v69–v77. doi:https://doi.org/10.1093/annonc/mdv222
   PubMed Web of Science ®Google Scholar
• Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res. 2011;4(4):486–501. doi:https://doi.org/10.1158/1940-6207.CAPR-10-0229
   PubMed Web of Science ®Google Scholar
• Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. JCO. 2013;31(12):1539–1547. doi:https://doi.org/10.1200/JCO.2012.45.2722
   PubMed Web of Science ®Google Scholar
• Planas M, Álvarez-Hernández J, León-Sanz M, Celaya-Pérez S, Araujo K, García de Lorenzo A. Prevalence of hospital malnutrition in cancer patients: a sub-analysis of the PREDyCES® study. Support Care Cancer. 2016;24(1):429–435. doi:https://doi.org/10.1007/s00520-015-2813-7
   PubMed Web of Science ®Google Scholar
• Pressoir M, Desné S, Berchery D, Rossignol G, Poiree B, Meslier M, Traversier S, Vittot M, Simon M, Gekiere JP, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010;102(6):966–971. doi:https://doi.org/10.1038/sj.bjc.6605578
   PubMed Web of Science ®Google Scholar
• Gellrich N-C, Handschel J, Holtmann H, Krüskemper G. Oral cancer malnutrition impacts weight and quality of life. Nutrients. 2015;7(4):2145–2160. doi:https://doi.org/10.3390/nu7042145
   PubMed Web of Science ®Google Scholar
• Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hütterer E, Isenring E, Kaasa S, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11–48. doi:https://doi.org/10.1016/j.clnu.2016.07.015
   PubMed Web of Science ®Google Scholar
• Hébuterne X, Lemarié E, Michallet M, de Montreuil CB, Schneider SM, Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN J Parenter Enteral Nutr. 2014;38(2):196–204. doi:https://doi.org/10.1177/0148607113502674
   PubMed Web of Science ®Google Scholar
• Attar A, Malka D, Sabaté JM, Bonnetain F, Lecomte T, Aparicio T, Locher C, Laharie D, Ezenfis J, Taieb J, et al. Malnutrition is high and underestimated during chemotherapy in gastrointestinal cancer: an AGEO prospective cross-sectional multicenter study. Nutr Cancer. 2012;64(4):535–542. doi:https://doi.org/10.1080/01635581.2012.670743
   PubMed Web of Science ®Google Scholar
• Gyan E, Raynard B, Durand J-P, Lacau Saint Guily J, Gouy S, Movschin ML, Khemissa F, Flori N, Oziel-Taieb S, Bannier Braticevic C, et al. Malnutrition in patients with cancer: comparison of perceptions by patients, relatives, and physicians-results of the NutriCancer2012 Study. JPEN J Parenter Enteral Nutr. 2017;42:260. doi:https://doi.org/10.1177/0148607116688881
   Web of Science ®Google Scholar
• Barao K, Forones NM. Body mass index: different nutritional status according to WHO, OPAS and Lipschitz classifications in gastrointestinal cancer patients. Arq Gastroenterol. 2012;49(2):169–71. doi:https://doi.org/10.1590/S0004-28032012000200013
   PubMedGoogle Scholar
• Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793–799. doi:https://doi.org/10.1016/j.clnu.2008.06.013
   PubMed Web of Science ®Google Scholar
• Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, Compher C, Correia I, Higashiguchi T, Holst M, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017;36(1):49–64. doi:https://doi.org/10.1016/j.clnu.2016.09.004
   PubMed Web of Science ®Google Scholar
• Vanhoutte G, van de Wiel M, Wouters K, Sels M, Bartolomeeussen L, De Keersmaecker S, Verschueren C, De Vroey V, De Wilde A, Smits E, et al. Cachexia in cancer: what is in the definition? BMJ Open Gastroenterol. 2016;3(1):e000097. doi:https://doi.org/10.1136/bmjgast-2016-000097
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495. doi:https://doi.org/10.1016/S1470-2045(10)70218-7
   PubMed Web of Science ®Google Scholar
• Reijnierse EM, de Jong N, Trappenburg MC, Blauw GJ, Butler-Browne G, Gapeyeva H, Hogrel J-Y, McPhee JS, Narici MV, Sipilä S, et al. Assessment of maximal handgrip strength: how many attempts are needed? J Cachexia Sarcopenia Muscle. 2017;8(3):466–474. doi:https://doi.org/10.1002/jcsm.12181
   PubMed Web of Science ®Google Scholar
• Grundmann O, Yoon SL, Williams JJ. The value of bioelectrical impedance analysis and phase angle in the evaluation of malnutrition and quality of life in cancer patients – a comprehensive review. Eur J Clin Nutr. 2015;69(12):1290–1297. doi:https://doi.org/10.1038/ejcn.2015.126
   PubMed Web of Science ®Google Scholar
• Barbosa-Silva MC, Barros AJ, Wang J, Heymsfield SB, Pierson RN. Bioelectrical impedance analysis: population reference values for phase angle by age and sex. Am J Clin Nutr. 2005;82(1):49–52. doi:https://doi.org/10.1093/ajcn/82.1.49
   PubMed Web of Science ®Google Scholar
• Bauer J, Capra S. Comparison of a malnutrition screening tool with subjective global assessment in hospitalised patients with cancer – sensitivity and specificity. Asia Pac J Clin Nutr. 2003;12:257–260.
   PubMed Web of Science ®Google Scholar
• Citak E, Tulek Z, Uzel O. Nutritional status in patients with head and neck cancer undergoing radiotherapy: a longitudinal study. Support Care Cancer. 2019;27(1):239–247. doi:https://doi.org/10.1007/s00520-018-4319-6
   PubMed Web of Science ®Google Scholar
• Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy-Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer . Value Health. 2009;12(1):124–129. doi:https://doi.org/10.1111/j.1524-4733.2008.00409.x
   PubMed Web of Science ®Google Scholar
• Cella D, Petrylak DP, Fishman M, Teigland C, Young J, Mulani P. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life? Eur Urol. 2006;49(5):781–789. doi:https://doi.org/10.1016/j.eururo.2005.12.058
   PubMed Web of Science ®Google Scholar
• Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. JCO. 2010;28(6):1054–1060. doi:https://doi.org/10.1200/JCO.2009.24.9730
   PubMed Web of Science ®Google Scholar
• Cushen SJ, Power DG, Murphy KP, McDermott R, Griffin BT, Lim M, Daly L, MacEneaney P, O' Sullivan K, Prado CM, et al. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel. Clin Nutr ESPEN. 2016;13:e39–e45. doi:https://doi.org/10.1016/j.clnesp.2016.04.001
   PubMedGoogle Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. doi:https://doi.org/10.1093/ageing/afy169
   PubMed Web of Science ®Google Scholar
• Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann Oncol. 2018;29(suppl_2):ii1–ii9. doi:https://doi.org/10.1093/annonc/mdx810
   Web of Science ®Google Scholar
• Laviano A, Rossi Fanelli F. Nutritional status is a predictor of outcome in cancer patients, irrespective of stage. Intern Emerg Med. 2017;12(1):135–136. doi:https://doi.org/10.1007/s11739-016-1539-y
   PubMed Web of Science ®Google Scholar
• Donini LM, Busetto L, Bauer JM, Bischoff S, Boirie Y, Cederholm T, Cruz-Jentoft AJ, Dicker D, Frühbeck G, Giustina A, et al. Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. Clin Nutr. 2020;39(8):2368–2388. doi:https://doi.org/10.1016/j.clnu.2019.11.024
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Halabi S, de Wit R, Tannock IF, Eisenberger M. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2009;12(1):88–93. doi:https://doi.org/10.1038/pcan.2008.36
   PubMed Web of Science ®Google Scholar
• Ohtaka A, Aoki H, Nagata M, Kanayama M, Shimizu F, Ide H, Tsujimura A, Horie S. Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy. Prostate Int. 2019;7(1):9–14. doi:https://doi.org/10.1016/j.prnil.2018.04.002
   PubMed Web of Science ®Google Scholar
• Massicotte M-H, Borget I, Broutin S, Baracos VE, Leboulleux S, Baudin E, Paci A, Deroussent A, Schlumberger M, Antoun S, et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab. 2013;98(6):2401–2408. doi:https://doi.org/10.1210/jc.2013-1115
   PubMed Web of Science ®Google Scholar
• Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW, et al. Pembrolizumab exposure–response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res. 2018;24(23):5841–5849. doi:https://doi.org/10.1158/1078-0432.CCR-18-0415
   PubMed Web of Science ®Google Scholar
• Roch B, Coffy A, Jean-Baptiste S, Palaysi E, Daures J-P, Pujol J-L, Bommart S. Cachexia – sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer. 2020;143:19–26. doi:https://doi.org/10.1016/j.lungcan.2020.03.003
   PubMed Web of Science ®Google Scholar
• Yap TA, Zivi A, Omlin A, de Bono JS. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8(10):597–610. doi:https://doi.org/10.1038/nrclinonc.2011.117
   PubMed Web of Science ®Google Scholar
• Cavka L, Pohar Perme M, Zakotnik B, Rotovnik Kozjek N, Seruga B. 676P prognostic role of nutritional status (NS) for health-related quality of life (HRQoL) in men with advanced prostate cancer (abstr). Abstract Book of the ESMO Virtual Congress 2020. Ann Oncol. 2020;31:S540. doi:https://doi.org/10.1016/j.annonc.2020.08.935
   Web of Science ®Google Scholar
• de van der Schueren MAE, Laviano A, Blanchard H, Jourdan M, Arends J, Baracos VE. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials. Ann Oncol. 2018;29(5):1141–1153. doi:https://doi.org/10.1093/annonc/mdy114
   PubMed Web of Science ®Google Scholar
• Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, Erickson N, Laviano A, Lisanti MP, Lobo DN, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017;36(5):1187–1196. doi:https://doi.org/10.1016/j.clnu.2017.06.017
   PubMed Web of Science ®Google Scholar
• McLaughlin K, Hedden L, Pollock P, Higano C, Murphy RA. Assessing the nutritional needs of men with prostate cancer. Nutr J. 2019;18(1):81. doi:https://doi.org/10.1186/s12937-019-0506-7
   PubMed Web of Science ®Google Scholar
• Benedetti MG, Furlini G, Zati A, Letizia Mauro G. The effectiveness of physical exercise on bone density in osteoporotic patients. Biomed Res Int. 2018;2018:1–10. doi:https://doi.org/10.1155/2018/4840531
   Web of Science ®Google Scholar
• Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. JCO. 2010;28(2):340–347. doi:https://doi.org/10.1200/JCO.2009.23.2488
   PubMed Web of Science ®Google Scholar
• Joseph JS, Lam V, Patel MI. Preventing osteoporosis in men taking androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2019;2(5):551–561. doi:https://doi.org/10.1016/j.euo.2018.11.001
   PubMed Web of Science ®Google Scholar